Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
|Articles|February 1, 2005
New agents show promise in melanoma
Tampa, Fla. — Among molecularly targeted agents being developed to treat melanoma, some of the most exciting are anti-CTLA-4 antibodies now being developed by Pfizer and Medarex.
Advertisement
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
Trending on Dermatology Times
1
Galderma to Acquire ZO Skin Health for $1.5 Billion
2
Exosome Progress and Remibrutinib Label Expansion
3
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
4
Chronic Hand Eczema Linked to Lost Productivity and Lower Quality of Life
5